Llovet, J. M. et al. Hepatocellular carcinoma. Nat. Rev. Dis. Primers 7, 6 (2021).
Vogel, A., Meyer, T., Sapisochin, G., Salem, R. & Saborowski, A. Hepatocellular carcinoma. Lancet 400, 1345–1362 (2022).
Llovet, J. M. et al. Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma. Nat. Rev. Clin. Oncol. 21, 294–311 (2024).
Li, X. et al. The immunological and metabolic landscape in primary and metastatic liver cancer. Nat. Rev. Cancer 21, 541–557 (2021).
Bader, J. E., Voss, K. & Rathmell, J. C. Targeting metabolism to improve the tumor microenvironment for cancer immunotherapy. Mol. Cell 78, 1019–1033 (2020).
Vander Heiden, M. G., Cantley, L. C. & Thompson, C. B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029–1033 (2009).
Doherty, J. R. & Cleveland, J. L. Targeting lactate metabolism for cancer therapeutics. J. Clin. Invest. 123, 3685–3692 (2013).
Payen, V. L., Mina, E., Van Hée, V. F., Porporato, P. E. & Sonveaux, P. Monocarboxylate transporters in cancer. Mol. Metab. 33, 48–66 (2020).
Lobel, G. P., Jiang, Y. & Simon, M. C. Tumor microenvironmental nutrients, cellular responses, and cancer. Cell Chem. Biol. 30, 1015–1032 (2023).
Wang, Z. H., Peng, W. B., Zhang, P., Yang, X. P. & Zhou, Q. Lactate in the tumour microenvironment: from immune modulation to therapy. EBioMedicine 73, 103627 (2021).
Chirnomas, D., Hornberger, K. R. & Crews, C. M. Protein degraders enter the clinic – a new approach to cancer therapy. Nat. Rev. Clin. Oncol. 20, 265–278 (2023).
Dale, B. et al. Advancing targeted protein degradation for cancer therapy. Nat. Rev. Cancer 21, 638–654 (2021).
Zhu, R., Zhang, H. & Chen, P. R. Targeted protein degradation in the transmembrane and extracellular space. Science 390, eadx5094 (2025).
Hinterndorfer, M., Spiteri, V. A., Ciulli, A. & Winter, G. E. Targeted protein degradation for cancer therapy. Nat. Rev. Cancer 25, 493–516 (2025).
Sakamoto, K. M. et al. Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proc. Natl Acad. Sci. USA 98, 8554–8559 (2001).
Banik, S. M. et al. Lysosome-targeting chimaeras for degradation of extracellular proteins. Nature 584, 291–297 (2020).
Ahn, G. et al. LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation. Nat. Chem. Biol. 17, 937–946 (2021).
Tang, X., Guo, N., Xu, L., Gou, X. & Mi, M. CD147/EMMPRIN: an effective therapeutic target for hepatocellular carcinoma. J. Drug Target. 21, 224–231 (2013).
Kirk, P. et al. CD147 is tightly associated with lactate transporters MCT1 and MCT4 and facilitates their cell surface expression. EMBO J. 19, 3896–3904 (2000).
Le Floch, R. et al. CD147 subunit of lactate/H+ symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumors. Proc. Natl Acad. Sci. USA 108, 16663–16668 (2011).
Schneiderhan, W. et al. CD147 silencing inhibits lactate transport and reduces malignant potential of pancreatic cancer cells in in vivo and in vitro models. Gut 58, 1391–1398 (2009).
Moad, G., Rizzardo, E. & Thang, S. H. Toward living radical polymerization. Acc. Chem. Res. 41, 1133–1142 (2008).
Zhou, Y. et al. Chemical proteomics reveal CD147 as a functional target of pseudolaric acid B in human cancer cells. Chem. Commun. 53, 8671–8674 (2017).
Spiess, M. The asialoglycoprotein receptor: a model for endocytic transport receptors. Biochemistry 29, 10009–10018 (1990).
Lin, W. et al. Tumor-intrinsic YTHDF1 drives immune evasion and resistance to immune checkpoint inhibitors via promoting MHC-I degradation. Nat. Commun. 14, 265 (2023).
Hong, C. S. et al. MCT1 modulates cancer cell pyruvate export and growth of tumors that co-express MCT1 and MCT4. Cell Rep. 14, 1590–1601 (2016).
Luri-Rey, C. et al. Cross-priming in cancer immunology and immunotherapy. Nat. Rev. Cancer 25, 249–273 (2025).
Xie, B. et al. Ms4a7 expression in cDC1s determines cross-presentation and antitumor immunity. Science 390, eady5362 (2025).
Wei, Y. et al. Plasma cell polarization to the immunoglobulin G phenotype in hepatocellular carcinomas involves epigenetic alterations and promotes hepatoma progression in mice. Gastroenterology 156, 1890–1904.e16 (2019).
Carmeliet, P. & Jain, R. K. Molecular mechanisms and clinical applications of angiogenesis. Nature 473, 298–307 (2011).
Wang, Y. et al. A nanoparticle-based strategy for the imaging of a broad range of tumours by nonlinear amplification of microenvironment signals. Nat. Mater. 13, 204–212 (2014).
Feng, Q. et al. Severely polarized extracellular acidity around tumour cells. Nat. Biomed. Eng. 8, 787–799 (2024).
Gatenby, R. A. & Gillies, R. J. Why do cancers have high aerobic glycolysis? Nat. Rev. Cancer 4, 891–899 (2004).
Lai, J. et al. Noninvasive small-animal imaging of galectin-1 upregulation for predicting tumor resistance to radiotherapy. Biomaterials 158, 1–9 (2018).
Moslehi, J., Lichtman, A. H., Sharpe, A. H., Galluzzi, L. & Kitsis, R. N. Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms. J. Clin. Invest. 131, e145186 (2021).
Liu, Q., Yin, X., Languino, L. R. & Altieri, D. C. Evaluation of drug combination effect using a Bliss independence dose-response surface model. Stat. Biopharm. Res. 10, 112–122 (2018).
Zhou, H. et al. Noninvasive interrogation of CD8+ T cell effector function for monitoring early tumor responses to immunotherapy. J. Clin. Invest. 132, e161065 (2022).
Shen, X. et al. 68Ga-grazytracer PET for noninvasive assessment of response to immunotherapy in solid tumors and lymphomas: a phase 1/2 clinical trial. Nat. Commun. 15, 8791 (2024).
Mehta, N. & Parikh, N. D. Too high, just right, or not enough? Rethinking α-fetoprotein thresholds for hepatocellular carcinoma screening. Gastroenterology 170, 468–469 (2026).
Hanif, H. et al. Update on the applications and limitations of alpha-fetoprotein for hepatocellular carcinoma. World J. Gastroenterol. 28, 216–229 (2022).
Zhang, Q. et al. Expression of CD147 as a significantly unfavorable prognostic factor in hepatocellular carcinoma. Eur. J. Cancer Prev. 16, 196–202 (2007).
Peng, F. et al. CD147 as a novel prognostic biomarker for hepatocellular carcinoma: a meta-analysis. BioMed Res. Int. 2017, 5019367 (2017).
James, M. L. & Gambhir, S. S. A molecular imaging primer: modalities, imaging agents, and applications. Physiol. Rev. 92, 897–965 (2012).
Ma, X. K. et al. 124I-labeled anti-CD147 antibody for noninvasive detection of CD147-positive pan-cancers: construction and preclinical studies. Acta Pharmacol. Sin. 45, 436–448 (2024).
Nambiar, D. M. et al. A novel CD147-targeting nanobody for immuno-PET imaging of liver cancer. J. Nucl. Med. (2026).
Xu, J. et al. A randomized controlled trial of licartin for preventing hepatoma recurrence after liver transplantation. Hepatology 45, 269–276 (2007).
Huang, W. et al. An anti-CD147 antibody-drug conjugate mehozumab-DM1 is efficacious against hepatocellular carcinoma in cynomolgus monkey. Adv. Sci. 12, e2410438 (2025).
Li, J. et al. A CD147-targeted small-molecule inhibitor potentiates gemcitabine efficacy by triggering ferroptosis in pancreatic ductal adenocarcinoma. Cell Rep. Med. 6, 102292 (2025).
Zheng, N. S. et al. CD147-specific chimeric antigen receptor T cells effectively inhibit T cell acute lymphoblastic leukemia. Cancer Lett. 542, 215762 (2022).
Yurchenko, V., Constant, S. & Bukrinsky, M. Dealing with the family: CD147 interactions with cyclophilins. Immunology 117, 301–309 (2006).
Rosenblum, D. et al. CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy. Sci. Adv. 6, eabc9450 (2020).
Liu, C. et al. Systemic reprogramming of tumour immunity via IL-10-mRNA nanoparticles. Nat. Nanotechnol. 20, 1526–1538 (2025).
Tang, C. et al. Co-delivery of sorafenib and an FSP1 inhibitor triggers dual ferroptosis in tumor cells and immunosuppressive macrophages for enhanced immunotherapy in mouse models of hepatocellular carcinoma. Nat. Commun. 16, 10096 (2025).
Chen, H., Zhang, W., Zhu, G., Xie, J. & Chen, X. Rethinking cancer nanotheranostics. Nat. Rev. Mater. 2, 17024 (2017).
Gawne, P. J., Ferreira, M., Papaluca, M., Grimm, J. & Decuzzi, P. New opportunities and old challenges in the clinical translation of nanotheranostics. Nat. Rev. Mater. 8, 783–798 (2023).
Zhang, D. et al. Transferrin receptor targeting chimeras for membrane protein degradation. Nature 638, 787–795 (2024).
Xiao, Y. et al. A covalent peptide-based lysosome-targeting protein degradation platform for cancer immunotherapy. Nat. Commun. 16, 1388 (2025).
Xiao, D. et al. Polyvalent folate receptor-targeting chimeras for degradation of membrane proteins. Nat. Chem. Biol. 21, 1731–1741 (2025).
Pance, K. et al. Modular cytokine receptor-targeting chimeras for targeted degradation of cell surface and extracellular proteins. Nat. Biotechnol. 41, 273–281 (2023).
Zhang, H. et al. Covalently engineered nanobody chimeras for targeted membrane protein degradation. J. Am. Chem. Soc. 143, 16377–16382 (2021).
Shi, T. et al. Dynamic reprogramming of the tumor immune network via multicycle checkpoint degradation for cancer immunotherapy. Proc. Natl Acad. Sci. USA 123, e2525047123 (2026).
Ahn, G. et al. Computational design of pH-sensitive binders. Preprint at bioRxiv (2025).
Du, J., Choi, B., Liu, Y., Feng, A. & Thang, S. H. Degradable pH and redox dual responsive nanoparticles for efficient covalent drug delivery. Polym. Chem. 10, 1291–1298 (2019).
Du, J. et al. Targeted protein degradation combined with PET imaging reveals the role of host PD-L1 in determining anti-PD-1 therapy efficacy. Eur. J. Nucl. Med. Mol. Imaging 51, 3559–3571 (2024).
Stuart, T. et al. Comprehensive integration of single-cell data. Cell 177, 1888–1902.e21 (2019).
Zhang, X. et al. CellMarker: a manually curated resource of cell markers in human and mouse. Nucleic Acids Res. 47, D721–D728 (2019).
Braun, D. A. et al. Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. Cancer Cell 39, 632–648.e8 (2021).
Magen, A. et al. Intratumoral dendritic cell-CD4+ T helper cell niches enable CD8+ T cell differentiation following PD-1 blockade in hepatocellular carcinoma. Nat. Med. 29, 1389–1399 (2023).
Ochocka, N. et al. Single-cell RNA sequencing reveals functional heterogeneity of glioma-associated brain macrophages. Nat. Commun. 12, 1151 (2021).
Zhang, T. et al. Annotation of CD8+ T-cell function via ICAM-1 imaging identifies FAK inhibition as an adjuvant to augment the antitumor immunity of radiotherapy. Theranostics 14, 699–713 (2024).
Zheng, C. et al. Nanobody PET tracer enables GPA33 expression profiling for precision diagnosis of colorectal cancer. Biophys. Rep. (2025).
